Rocket Pharma Gets Regenerative Medicine Advanced Therapy Designation for RP-L301
23 Maio 2023 - 8:51AM
Dow Jones News
By Chris Wack
Rocket Pharmaceuticals said Tuesday that the U.S. Food and Drug
Administration has granted a regenerative medicine advanced therapy
designation to RP-L301, the company's investigational
lentiviral-based gene therapy for pyruvate kinase deficiency.
The Cranbury, N.J.-based late-stage biotechnology company said
RMAT designation was granted based on RP-L301's robust safety and
efficacy data from an ongoing Phase 1 clinical trial, and its
potential to cure a life-threatening disease for which no curative
therapies currently exist.
The RMAT designation will provide the benefits of added FDA
guidance and expedited review throughout the RP-L301 program's
development. RP-L301 has also received the FDA's fast track and
orphan drug designations.
Rocket Pharma said RP-L301's safety profile appears highly
favorable, with no RP-L301-related serious adverse events in either
of the adult patients.
The program's first pediatric patient results suggest efficacy
similar to the adult cohort with an initial greater than a
five-point increase in hemoglobin. The infusion was well-tolerated,
and no RP-L301-related serious adverse events or red blood cell
transfusion requirements followed engraftment.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
May 23, 2023 07:36 ET (11:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Rocket Pharmaceuticals (NASDAQ:RCKT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Rocket Pharmaceuticals (NASDAQ:RCKT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024